• Prescribing Information
  • Medical Information
  • Safety Profile and Tolerability

    TRUMENBA has a safety profile established in 11 clinical trials and more than 15,000 individuals worldwide.1

    The safety data demonstrated that TRUMENBA was generally well tolerated.1
    The most common solicited adverse reactions in adolescents and young adults were1

    • Pain at the injection site (≥85%)
    • Muscle pain (≥35%)
    • Fatigue (≥60%)
    • Headache (≥55%)

    Nausea was reported in up to 24% of adolescents in early phase studies.1

      • In clinical trials, the frequencies of adverse events occurred at lower rates with second and third doses of TRUMENBA compared with the first dose1

      TRUMENBA is the only MenB vaccine with prefilled syringes not made with natural rubber latex.1

          • The tip cap and rubber plunger are not made with natural rubber latex

            Real world experience

            TRUMENBA was selected for use in mass vaccination efforts against MenB outbreaks in the US at Providence College and the University of Oregon in 20152,3

            Card CTA

            Use in Specific Populations1

                • Pregnancy: There are no adequate and well-controlled studies of TRUMENBA in pregnant women
                • Lactation: Available data are not sufficient to assess the effects of TRUMENBA on the breastfed infant or on milk production/excretion
                • Pediatric use: Safety and effectiveness have not been established in children <10 years of age. In a clinical study, 90% of infants <12 months of age who were vaccinated with a reduced dosage formulation had fever
                • Geriatric use: Safety and effectiveness in adults >65 years of age have not been established

                  Contact your Pfizer Sales Representative or call a Vaccine Specialist at
                  1-844-439-2571.


                  References:
                  1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.
                  2. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR. 2015;64(22):606-607.
                  3. McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak—Oregon, 2015–2016. J Infect Dis. 2017;216(9):1130–1140.
                  4. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed July 6, 2020.
                  5. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450.
                  6. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9.
                  7. Ewald AJ, McKeag DB. Meningitis in the athlete. Curr Sports Med Rep. 2008;7(1):22-27.

                  Efficacy & Safety

                  • Safety Profile and Tolerability
                  • Immunogenicity & Persistence

                  Pfizer TruSupport

                  • Ordering options​​​​​​​
                  • Patient coverage confirmation​​​​​​
                  • Essential tools
                  • Resources for your practice
                  Find out about TruSupport

                  Why adolescents and young adults?

                  Typical adolescent and young adult behaviors increase MenB risk.7-10​​​​

                  Learn about MenB

                  The science behind TRUMENBA

                  Only TRUMENBA targets both subfamilies, A and B, of fHBP.1

                  See the science

                  Indication

                  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
                  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
                  • Severe allergic reaction after a previous dose of Trumenba is a contraindication
                  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
                  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
                  • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
                  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
                  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
                  • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
                  • Safety and effectiveness have not been established in pregnant women
                  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
                  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

                  Please see full Prescribing Information.​​​​​​​